Lesson plan
Ensitrelvir
Ensitrelvir, sold under the brand name Xocova, is an antiviral medication used as a treatment for COVID-19 and as post-exposure prophylaxis (PEP) to prevent COVID-19 infections following exposure. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth. The most common adverse events include transient decreases in high-density lipoprotein and increased blood triglycerides.
Article summary
Ensitrelvir, sold under the brand name Xocova, is an antiviral medication used as a treatment for COVID-19 and as post-exposure prophylaxis (PEP) to prevent COVID-19 infections following exposure. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth. The most common adverse events include transient decreases in high-density lipoprotein and increased blood triglycerides.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.